Pox-Protein Public-Private Partnership (P5)
{"Image DocumentName": "Pox-Protein Public-Private Partnership (P5)", "Image ImageDescription": "Established in 2010 to build on the RV144 results. Seeks to advance and ultimately license HIV pox-protein vaccine candidates that have the potential to achieve a broad public health impact. The Phase III HIV Vaccine Trial, also known as RV144, was the largest HIV vaccine study ever conducted in humans and involved more than 16,000 volunteers in Thailand. The trial tested a prime-boost combination of two vaccines and provided first evidence that an HIV vaccine is possible.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}